"I Am the Only Normal Person in My Universe," the definitive Book about Relational Intelligence, (RQ) written by Richard Zwicky

Richard Zwicky, founder and CEO of Memores Software, published "I Am the Only Normal Person in My Universe," a book presenting a framework for Relational Intelligence and interpersonal conflict. Written during his recovery from Long COVID, the publication is connected to Memores' Sparks-Health Relational Intelligence Platform but contains no financial results, guidance, or material commercial metrics.

Analysis

This is not investable public-market information and offers no evidence of customer adoption, recurring revenue, reimbursement coverage, clinical validation, or distribution economics. The relevant diligence question is whether relational-intelligence tools can move from wellness content into employer-sponsored behavioral-health benefits, where procurement cycles and proof-of-outcomes requirements are substantially higher than consumer engagement claims.

The nearest public read-through is limited: if such platforms gain measurable traction, they would compete at the margin for employer wellness budgets with TELADOC (TDOC), AMWELL (AMWL), and digital mental-health vendors rather than alter the core economics of managed-care incumbents. A book-led awareness effort is more likely a low-cost brand and lead-generation channel than a material product catalyst; absent disclosed contracted lives, retention, or outcomes data, there is no basis to underwrite a valuation impact over the next 6-18 months.

Contrarianly, the crowded digital-health narrative tends to overvalue engagement metrics while underweighting buyer consolidation and reimbursement pressure. Any future commercial traction would be more strategically relevant to HR-benefits aggregators and insurers seeking lower-acuity intervention tools, but it would need independently validated reductions in absenteeism, claims utilization, or behavioral-health escalation to overcome the sector's credibility discount.

Key Decisions for Investors

• No trade: do not infer a public-equity catalyst from this announcement; impact is immaterial without disclosed enterprise contracts, annual recurring revenue, or independently verified clinical/economic outcomes.
• Add an alert for TDOC and AMWL only if the company discloses a material payer, employer-benefits, or channel partnership with contracted-member metrics; assess whether the tool is incremental to existing platforms or substitutes for reimbursed care.
• For digital-health exposure, maintain a quality bias toward companies demonstrating reimbursement durability and positive EBITDA/FCF rather than engagement-led wellness platforms; falsification would be sustained evidence that non-clinical tools reduce medical-cost trends enough to secure payer reimbursement.